A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies-Reference-Cited by-同舟云学术

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Published:2013-03-25 Issue:1 Volume:13 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Goldman Jonathan W,Raju Robert N,Gordon Gregory A,El-Hariry Iman,Teofilivici Florentina,Vukovic Vojo M,Bradley Robert,Karol Michael D,Chen Yu,Guo Wei,Inoue Takayo,Rosen Lee S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-13-152.pdf

Reference37 articles.

1. Zuehlke A, Johnson JL: Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers. 2010, 93 (3): 211-217. 10.1002/bip.21292.

2. da Silva VC, Ramos CH: The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics. J Proteomics. 2012, 75 (10): 2790-2802. 10.1016/j.jprot.2011.12.028.

3. Neckers L, Workman P: Hsp90 molecular chaperone inhibitors: are we there yet?. Clin Cancer Res. 2012, 18 (1): 64-76. 10.1158/1078-0432.CCR-11-1000.

4. Whitesell L, Lin NU: HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim Biophys Acta. 2012, 1823 (3): 756-766. 10.1016/j.bbamcr.2011.12.006.

5. Maloney A, Clarke PA, Workman P: Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr Cancer Drug Targets. 2003, 3 (5): 331-341. 10.2174/1568009033481822.

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer;Leukemia;2024-04-18

2. Molecular Pathways Governing the Termination of Liver Regeneration;Pharmacological Reviews;2024-03-04

3. Protective role of the HSP90 inhibitor, STA-9090, in lungs of SARS-CoV-2-infected Syrian golden hamsters;BMJ Open Respiratory Research;2024-02

4. Promising targetable biomarkers in pancreatic neuroendocrine tumours;Expert Review of Endocrinology & Metabolism;2023-09-03

5. Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice;International Journal of Molecular Sciences;2023-03-06